Mondias Announces an Amendment to its Stock Option Plan
Momentum Public Relations
Press Release: February 11, 2019
Mondias Natural Products Inc. (TSXV: NHP) (“Mondias” or the “Corporation”), a Corporation that specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets, announces that its Board of Directors has approved an amendment to its stock option plan to become effective upon approval by the shareholders of the Corporation at the Annual General Meeting of shareholders to be held later this year and upon receipt of final approval by the TSX Venture Exchange Inc. A copy of the proposed Stock Option Plan will be available from the Chief Executive Officer of the Corporation upon request and will be attached to the Information Circular to be filed on SEDAR, at www.sedar.com, for the upcoming Annual General Meeting of the shareholders.
The Corporation proposes to replace the fixed 20% stock option plan with a rolling 10% stock option plan. Under the rolling 10% stock option plan, the Corporation may grant options to acquire common shares of the Corporation equal to 10% of the issued and outstanding shares from time to time subject to the terms and conditions prescribed by the TSX Venture Exchange Inc. and applicable securities laws.
Currently outstanding options to purchase common shares of the Company granted prior to the amendment will continue to be exercisable and will be governed by and subject to the terms of the amended plan.
Based on the Company’s current issued and outstanding common share amount of 63,135,805, the amended rolling plan maximum is currently 6,313,581 common shares. Prior to the amendments to the plan, the fixed plan maximum was 400,408 common shares.
On January 22, 2019, the Board of Directors had approved the grant, subject to shareholder and regulatory approval, of incentive stock options under the amended 2019, 10% Rolling Stock Option Plan to the directors and officers of the Corporation for the purchase of a total of 2,550,000 shares in its capital. The options are exercisable before January 22, 2029, at the price of $0.235 per share (the closing price of the shares on January 21, 2019). The stock options vest over a 3-year period, with the first vesting period delayed until all regulatory and shareholder approvals are received.
About Mondias Natural Products Inc. Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit : mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Mondias Natural Products Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2019/11/c1683.html
Contact:
Jean Philippe Gravel, CEO, Telephone: 514-804-4569, Email : jpgravel@mondias.ca
- Published in Business, Life Sciences, Mondias Natural, News Home
Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067
Momentum Public Relations
Press Release: February 06, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona’s skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
The skincare company has completed extensive due diligence on TFC-1067. This includes both the data package provided by Sirona as well as their independent research and analysis on the compound. This work is contributing to the goal of an international commercial launch of what we are proving will be both a safe and effective skin lightener in an industry where other compounds typically suffer from either poor efficacy or toxicity issues.
The ROFR agreement, which includes all territories except China, states that upon receipt of the clinical trial report from dermatologist Dr. Zoe Draelos, the company will have 30 days to review the data. At that time, the company will notify Sirona of their intent to conclude a licensing agreement. At their request, the company’s identity and the detailed agreement will remain confidential until a definitive agreement is executed.
Sirona has received an up-front payment for the acceptance of the ROFR.
“We are very pleased to have established this arrangement. A great deal of time and resources have been invested by both Sirona and the skincare company working on the advancement of TFC-1067 with the goal of an international commercial launch”, reports Dr. Howard Verrico, CEO of Sirona. “In order to protect the company and justify their ongoing efforts, the ROFR was a necessary step in advance of our clinical trial results, as these results are also greatly anticipated by other major skincare companies. This is an exciting time for Sirona’s team here in Canada as well as our scientific team in France and marks another milestone towards commercially launching a disruptive new skin lightening ingredient in this 20 Billion USD global skin lightening market1.”
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and research dermatologist based in High Point, North Carolina. Dr. Draelos, supported by a team of highly skilled scientists, is the head of the Dermatology Consulting Services (DCS) research organization, aimed at facilitating research, consulting and communication services to the pharmaceutical and cosmetic industries. The clinical trial center runs assessments on different skin, hair and nail conditions, such as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been recognized many times over the years for her cutting-edge research, including the lifetime achievement award from Health Beauty America and the Society of Cosmetic Chemists. A pioneer in the field of cosmetic dermatology, Dr. Draelos continues to work with lead cosmetic and pharmaceutical companies as well as furthering her own research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of Dermatology and is a Consulting Professor of Dermatology at Duke University. She has authored over 300 articles, 8 books and has shared her expertise across different media.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
1 |
Fact.MR (July 2018) Retrieved from: https://globenewswire.com/news-release/2018/07/10/1535161/0/en/Key-Insights-on-Skin-Lightening-Products-Market-through-2022-by-Fact-MR.html |
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2019/06/c8940.html
Contact:
regarding this press release, please contact: Christopher Hopton, CFO, Sirona Biochem Corp., Phone: 1.604.282.6064, Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
Tetra Bio-Pharma Redefines Quality Standards for Pharmaceutical Grade Cannabis-Derived Products
Momentum Public Relations
Press Release: February 05, 2019
Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has temporarily suspended its phase 3 clinical program due to impurities found in its PPP001 investigational drug being administered to patients. This suspension does not affect the timing of the European application nor the development of the second-generation inhalation products.
Quality standards and process validations are imposed by pharmaceutical Good Manufacturing Practices (GMP). Just like our food chain, botanical drugs have unique challenges because of the potential for microbial contamination known as mycotoxins. Tetra’s investigational drug is composed of raw cannabis materials. In late spring 2018, Tetra initiated a study to monitor the microbial flora in its investigational product in order to validate the storage and drying process used in the fabrication of its investigational product. On December 20th the results of this ongoing study revealed the presence of the 3 mycotoxins in the lot of the investigational drug used for the clinical trials. Tetra communicated these findings within 24-hours of discovery to regulators and acted rapidly to ensure the safety and wellness of patients. As per discussions with Health Canada and the Ethics Review Board, Tetra contacted every patient involved in the ongoing clinical trials to suspend treatment and retrieve the investigational drugs.
Cannabis products that are ultimately sold in the recreational or medical market in Canada, are cultivated, processed and sold under the Cannabis Act, which are subject to Good Production Practices. Under the Good Production Practices, there is only a requirement to test for certain mycotoxins, namely aflatoxin and total content of mycotoxins. The cannabis raw materials purchased by Tetra for use in its investigational drug met the requirements under the Cannabis Act and Good Production Practices and tested below allowable limits.
However, Tetra is administering cannabis to patients as a drug for use in clinical trials which is governed by the requirements of the Food and Drugs Act and related Regulations. The fabrication, processing, packaging and sale of the investigational drug, must be conducted in accordance with the Good Manufacturing Practices (“GMPs”). Such GMPs require the validation of the storage and drying process to ensure the cannabis drug conforms to the quality standard of a prescription drug. Tetra, having acted in accordance with the requirements of the Food and Drugs Act and GMPs, detected the presence of mycotoxins other than aflatoxin in the experimental lot used for the validation. This led to the analyses of every lot being used in its clinical trials to verify for the presence of two other types of mycotoxins (Ochratoxin A, and DON (Deoxynivalenol; Vomitoxin) and the inclusion of this testing into the product specifications.
Tetra Bio-Pharma considers patient health and well-being to be non-negotiable. Tetra will take the next 6 months to assess the situation and propose a robust quality program to Health Canada so that Canadian patients taking its PPP001 prescription cannabis-derived drug are confident in the products’ quality and safety.
Tetra Bio-Pharma CEO and CSO Guy Chamberland holds a Ph.D. in Biomedical Sciences (toxicology) among other academic designations and is a well-respected expert in the field particularly in drug safety stated, “This unexpected development will result in a 6-month delay in the submission of the Canadian New Drug Submission or Drug Identification Number (DIN) application for PPP001. Tetra strongly believes that this delay will lead to a safer and higher quality drug for patients with advanced cancer. Through our research and development efforts, Tetra’s intention is to create higher quality for all cannabis-derived medicinal products. This is Tetra’s commitment to patient safety. We will continue to provide reports to Health Canada so that the Canadian government receives Tetra’s data in a timely manner so that regulators can ensure the safety and wellness of all Canadians consuming recreational and medical cannabis.”
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc.
Momentum Public Relations
Press Release: January 30, 2019
Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc.
Canada NewsWire
ORLEANS, ON, Jan. 30, 2019
The Proposed Transaction is expected to:
- provide Tetra with the most robust Pharmaceutical and Natural Health Products pipeline of any Cannabinoid company;
- provide Tetra with more pharmaceutical and natural health products;
- allow Tetra to sell these products worldwide;
- give Tetra access to Panag’s NHP portfolio which is not included in the present in-licensing agreement with Panag.
ORLEANS, ON, Jan. 30, 2019/CNW Telbec/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“), a leader in cannabinoid-based drug discovery and development (TSXV: TBP) (OTCQB: TBPMF), today announced it has entered into a definitive agreement (the “Agreement“) with the shareholders (the “Vendors“) of Panag Pharma Inc. (“Panag“) for the previously-announced acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the “Proposed Transaction“). Panag is a Canadian-based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag has developed innovative and patented formulations for the treatment of ocular diseases and other pain conditions such as general neuropathic pain. Their significant formulation expertise in the wellness market will allow Tetra to expand its commercial operations.
Dr. Guy Chamberland, CEO and CSO of Tetra stated, “In completing this acquisition of Panag Pharma we have not only acquired a large portfolio of cannabinoid derived pharmaceutical and natural health products but also a team of scientists that have a substantial amount of expertise in the field. Tetra Bio-Pharma looks forward to incorporating Panag into its operations and accelerating its various drug development programs including our second-generation inhaled program.”
Following the closing of the Proposed Transaction, it is expected that Panag will remain a separate subsidiary owned 100% by Tetra and provide Tetra with additional discovery and early phase drug development capacity. With this robust product pipeline, Tetra intends to continue to implement its out-licensing program to generate additional revenues via upfront payments, milestone payments, and royalties and actively pursue the clinical development of lead products.
According to Dr. Orlando Hung, a co-founder of Panag, “The Panag team is very excited to have this well-timed opportunity with Tetra Bio-Pharma, allowing us to continue our decades of translational cannabinoid research. Utilizing the expertise and support from Tetra Bio-Pharma, we are confident that our partnership and combined skills will position us to bring effective and safe cannabinoid-based medications, as well as more innovative cannabinoid delivery systems to market to help managing patients with pain and inflammation.”
Pursuant to the Agreement, Tetra would acquire 100% of the issued and outstanding shares of Panag for an aggregate consideration of $12,000,000, on a debt-free basis and subject to customary post-closing adjustments. The purchase price would be payable by Tetra delivering to the Vendors, on the closing date of the Proposed Transaction, (i) $3,000,000 in cash and (ii) $9,000,000 payable in common shares of Tetra (“Common Shares“), at a price per Common Share equal to the lesser of (i) the 10-day volume weighted average price of the Common Shares ending as of the date of the Agreement and (ii) the Discounted Market Price (as that term is defined in the policies of the TSX Venture Exchange (“TSXV“)) of the Common Shares as at the date that is three business days prior to the closing date of the Proposed Acquisition. The Agreement also contemplates the payment by Tetra to the Vendors of an aggregate amount of up to $15,000,000 in cash in milestone payments upon the achievement of operational targets associated with marketing approvals and commercialization of both human and veterinary drug products by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Tetra is committed to fund Panag’s research in an amount no less than $1,200,000 annually for a period of ten years after the closing date of the Proposed Acquisition. The milestone payments would be accelerated in the event of a bankruptcy, insolvency, failure of Tetra to make its funding commitments to Panag, change of control or sale of all of the assets of Tetra at any time until December 31, 2028. In addition, in the event of a change of control of Tetra within 24 months of the closing date of the Proposed Acquisition, the Vendors would be entitled to receive from Tetra an additional $10 million.
Two of the Vendors, Bill Cheliak and Gregory Drohan, are non-arm’s length parties to Tetra within the meaning of the rules of the TSXV. Mr. Cheliak is the Chairman of the board of directors of the Company (the “Board“) and Mr. Drohan is a director of the Company. The Proposed Transaction will not result in the issuance of securities to non-arm’s length parties as a group as payment of the purchase price exceeding 10% of the number of outstanding shares of the Company on a non-diluted basis.
The Board formed a special committee (the “Special Committee“) for purposes of evaluating the Proposed Transaction. The Special Committee was composed of Benoit Chotard and Carl Merton, both of whom have no interest in Panag or the Proposed Transaction. On December 24, 2018, the Special Committee received a fairness opinion (the “Fairness Opinion“) from Paradigm Capital stating that the purchase price under the Proposed Transaction is fair, from a financial point of view, to the shareholders of Tetra. In light of the Fairness Opinion and of other considerations and upon the recommendation of the Special Committee, the Board approved the Proposed Transaction. Because of their interests in the Proposed Transaction, Mr. Cheliak and Mr. Drohan recused themselves from all meetings and discussions of the Board relating to the Proposed Transaction and abstained from voting on the resolutions of the Board approving the Proposed Transaction.
The Company expects that the Proposed Transaction will be completed in February 2019. Completion of the Proposed Transaction remains subject to a number of conditions, including the receipt of the approval of the TSXV and such other closing conditions as are customary in transactions of this nature. There can be no assurance that such conditions will be satisfied and that the Proposed Transaction will be completed as described or at all.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Panag Pharma:
Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new approach to the treatment of chronic pain and inflammation.
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
DIAGNOS Welcomes Dr. Jean-Francois Yale to the Board of Directors
Momentum Public Relations
Press Release: January 29, 2019
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment of Dr. Jean-Francois Yale to its board of directors.
Dr. Yale is an endocrinologist, currently professor of medicine at the McGill University Department of Medicine. Dr. Yale chaired the Clinical and Scientific Section of the Canadian Diabetes Association from 1992-1994 as well as the Expert Committee that published the 2001 Clinical Practice Guidelines for the Prevention and Management of Diabetes. Dr. Yale’s research interests (210 publications) include the prevention of hypoglycemia in type 1 diabetes and he participated in numerous multicentre trials on new therapies for type 1 and type 2 diabetes.
“We are delighted to have Dr. Yale joining the Board. I am convinced that DIAGNOS will greatly benefit from his specialized interest in intensive management of type 1 and type 2 diabetes,” said Mr. Georges Hebert, Chairman of the board of directors of DIAGNOS.
The board of directors has approved a grant of 2,620,000 stock options to the directors and officers of the Corporation. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price of these options has been established at $0.05 per share. The expiry date to which these options can be exercised has been fixed to January 28, 2024.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com
- Published in Diagnos, Life Sciences, News Home, Technology
Mondias announces agreement with Wisdom of Nature Brokerage to expand retail sales in Ontario and grants stock options
Momentum Public Relations
Press Release: January 25, 2019
Mondias Natural Products Inc (“Mondias” or “Company“), (TSX VENTURE: NHP) announces the signing of a sales representation agreement with Wisdom of Nature Brokerage, a company specializing in the retail sales of Natural Health Products in Ontario. Mondias through its recently acquired Holizen brand, has been operating successfully in the province of Quebec and is now expanding retail operations to Ontario for the first phase of its Canada wide distribution.
Other news
The Board of Directors of the Company has approved the granting of 2,550,000 stock options to directors, officers, consultants and employees of the Company. The exercise price of the options is $0.235 (the closing price of the shares on January 21, 2019). The options vest over a 3-year period.
The above-mentioned options have been granted pursuant to the Mondias’s Stock Option Plan. Following this stock option grant the Company has a total of 2,950,804 stock options outstanding, which represents less than 5% of the Company’s issued and outstanding common shares.
About Wisdom of Nature Inc.
With more than 25 years of experience in the Natural Health Food Industry, Wisdom of Nature, led by its president and CEO Corine Johnson, specializes in sales development and independent/mass market product listing across the province of Ontario. They represent top brands like Strauss, Joy of the Mountain, Nature’s Aid, Abundance Naturally, Cannanda and Pro Santé.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit : mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Life Sciences, Mondias Natural, News Home, Technology
DIAGNOS Announces an Extension to the Diabetic Retinopathy Screening Services Assisted by Artificial Intelligence (AI) at the CHUM
Momentum Public Relations
Press Release: January 22, 2019
DIAGNOS Inc. (“DIAGNOS” or the “Company”) (TSX Venture Exchange: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today, further to our initial news release dated June 5th, 2018, the extension through May 2019 of the technological showcase for the automated detection of Diabetic Retinopathy at the Centre Hospitalier de l’Université de Montréal (CHUM).
Technological showcase
DIAGNOS will continue screening for diabetic retinopathy at the CHUM until the end of May 2019. Because of excellent initial screening results, the administration of the CHUM has elected to extend the duration of the technological showcase to further appreciate the benefits.
AI for detection and triage
Our early detection service includes an automated AI analysis of fundus imagery together with a triage system according to the degree of severity. This proprietary service is only available via our CARA telehealth platform (Computer Assisted Retina Analysis).
Improving patient services
The DIAGNOS automated screening solution significantly increases accessibility for diabetic and hypertensive patients subject to annual screening. Screening is done at the service centre using fundus photography. The process is fast, painless, and very simple for the patient. The CARA platform will facilitate identification and expedited triage of patients suffering from retinopathies who have been referred to the ophthalmology department following a consultation at the endocrinology or diabetes clinic.
DIAGNOS is also announcing the resignation of Mr. Jean-Yves Thérien from his position as director and chairman of the audit committee of the Corporation due to personal reasons. “On behalf of my fellow board members, I would like to sincerely thank Jean-Yves for his dedication and important contribution to the development of DIAGNOS”, said Mr. Georges Hébert, Chairman of the Board of directors. The Corporation is in the process of finding Mr. Thérien’s replacement as chairman of the audit committee. In the interim, Mr. Hébert will assume the role of chairman of the audit committee.
About DIAGNOS
DIAGNOS has screened to date more than 250,000 diabetic patients. Thanks to the support of the Government of Quebec and our collaboration with the CHUM, this technological showcase will allow Diagnos to demonstrate our expertise in the province. We strongly believe this partnership will also help set up extensive screening campaigns in other Canadian provinces and in the United States.
About CARA
CARA is a proprietary tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com
- Published in Diagnos, Life Sciences, News Home, Technology
Diagnos 900,000 shares for debt
Momentum Public Relations
Press Release: December 12, 2018
The TSX Venture Exchange has accepted for filing the company’s proposal to issue 900,000 common shares at a price of five cents per share in settlement of a total amount of $45,000 on outstanding interest payable on convertibles notes issued in October, 2017.
Number of creditors: seven creditors
Insiders: Gestion Maurice Pinsonnault (Maurice Pinsonnault), 200,000; Danie Clerk, 200,000
For further information, please refer to the company’s press releases dated Oct. 24, 2018, and Nov. 21, 2018.
- Published in Diagnos, Life Sciences, News Home, Technology
Tetra Bio-Pharma Confirms Agreements With Multiple Suppliers
Momentum Public Relations
Press Release: December 11, 2018
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF) a leader in cannabinoid-based drug discovery and development confirms its non-exclusive supply agreement for GMP-Grade THC with U.S.-based Rhodes Technologies Inc. The supply will be used for several drug development activities including Tetra’s cannabinoid-derived products PPP002, PPP003, and PPP004, as well as for discovery phase projects. This is additional to having a supply agreement with True North Cannabis Inc. for CBD from hemp which was necessary to meeting the demand associated with the Genacol Corporation transaction.
“With a robust development pipeline, it is essential for Tetra to have a reliable, API supply to support our expanding needs and avoid product shortages,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “Our agreement with Rhodes is predicated on their long history and expertise in the production and sale of active chemical ingredients, particularly in the area of pain management. In terms of CBD, our suppliers are selected based on their ability to provide us with both quality (GMP Pharmaceutical Grade) and volume. Tetra is always mindful of the need to have consistent supply as well as back-ups for each of the products under development.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Sirona Biochem’s SGLT2 Inhibitor in Testing for Animal Health
Momentum Public Relations
Press Release: December 11, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announced today that testing has commenced for the SGLT2 inhibitor, TFC-039, in cats.
Several months ago, Sirona was approached by a company to test TFC-039 as a drug for treating diabetes in cats and dogs. The company requested to remain confidential.
A proof of concept study has begun to evaluate the glucosuria effect of TFC-039. This will address the simple question of whether the molecule engages with the feline receptor in a manner that would make TFC-039 a suitable drug development candidate. Results for this initial study are expected later this month.
“We are excited about the prospect of our SGLT-2 inhibitor being used in not only another market outside of China, but in other species as well,” said CEO Dr. Howard Verrico. “The upside to developing a drug for animals includes faster approval, less competition with generics and longer product life. The global pet healthcare market is projected to reach 65 billion USD by 2025. Diabetes is a common illness in pets, particularly in felines. This is attributed in part due to increasing pet ownership, increasing obesity rates, and improved rates of diagnosis. There is also a growing trend to treat the pets suffering from this illness to allow them to live near normal lifespans.”
If successful, the company’s primary focus would be to create the drug for the North American and European markets, followed by Japan and Australia. The market continues to grow, at roughly 5%. Sirona is looking forward to continuing the collaboration with this company.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in Life Sciences, News Home, Sirona Biochem